Skip to main content

Table 1 Baseline characteristics in patients with or without CAD and CAP

From: Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus

Variables

Total

CAD

Non-CAD

P value

CAP

Non-CAP

P value

(n = 302)

(n = 232)

(n = 70)

(n = 165)

(n = 137)

Baseline characteristics

 Age, years

57.52 ± 10.56

58.08 ± 10.48

55.66 ± 10.72

0.093

59.10 ± 11.01

55.61 ± 9.70

0.004

 Male, n (%)

196 (64.9)

163 (70.3)

33 (47.1)

< 0.001

113 (68.5)

83 (60.6)

0.152

 BMI, kg/m2

26.43 ± 3.15

26.36 ± 3.07

26.57 ± 3.41

0.648

26.32 ± 3.11

26.51 ± 3.20

0.606

 Family history of CAD, n (%)

42(13.9)

32(13.8)

10(14.3)

0.855

22(13.3)

20(14.6)

0.758

 HTN, n (%)

217 (71.9)

177 (76.3)

40 (57.1)

0.002

127 (77.0)

90 (65.7)

0.030

 Stroke, n (%)

17 (5.6)

12 (5.2)

5(7.1)

0.519

12 (7.3)

5 (3.6)

0.192

 Smoking, n (%)

154 (51.0)

126(54.3)

28 (40.0)

0.028

91 (55.2)

63 (46.0)

0.129

 Alcohol drinker, n(%)

102 (33.8)

80(34.5)

22 (31.4)

0.557

63 (38.2)

39 (28.5)

0.085

Laboratory parameters

 FPG, mmol/L

7.42 ± 2.16

7.63 ± 2.27

6.68 ± 1.54

< 0.001

7.57 ± 2.20

7.24 ± 2.11

0.185

 HbA1c (%)

7.33 ± 1.32

7.49 ± 1.36

6.77 ± 0.98

< 0.001

7.41 ± 1.29

7.24 ± 1.35

0.289

 TC, mmol/L

4.29 ± 1.29

4.21 ± 1.32

4.55 ± 1.16

0.056

4.39 ± 1.45

4.17 ± 1.06

0.127

 LDL-C, mmol/L

2.61 ± 1.10

2.55 ± 1.13

2.83 ± 0.99

0.066

2.70 ± 1.26

2.51 ± 0.86

0.114

 HDL-C, mmol/L

1.02 ± 0.28

1.01 ± 0.29

1.03 ± 0.26

0.697

1.03 ± 0.29

1.00 ± 0.26

0.315

 TG, mmol/L

1.64(1.25–2.41)

1.62(1.22–2.39)

1.93(1.31–2.63)

0.211

1.69(1.21–2.58)

1.58(1.29–2.37)

0.854

 ApoA, g/L

1.33 ± 0.43

1.33 ± 0.47

1.37 ± 0.26

0.481

1.37 ± 0.52

1.29 ± 0.28

0.131

 ApoB, g/L

0.90 ± 0.30

0.88 ± 0.30

0.94 ± 0.29

0.168

0.89 ± 0.32

0.91 ± 0.27

0.52

 Lp(a), mg/dL

115.34

(53.68–281.85)

112.35

(53.9–299.98)

122.1

(52.95–231.38)

0.933

110.1

(60.25–253.0)

125.7

(45.1–334.6)

0.622

 Hs-CRP, mg/dL

1.45(0.77–2.78)

1.46(0.77–2.73)

1.39(0.69–2.87)

0.824

1.51(0.87–2.87)

1.37 (0.61–2.65)

0.289

 LVEF (%)

63.23 ± 7.44

62.67 ± 7.92

65.04 ± 5.23

0.021

62.64 ± 7.69

63.91 ± 7.10

0.147

 FFAs, mmol/L

0.49 ± 0.17

0.51 ± 0.17

0.41 ± 0.15

< 0.001

0.54 ± 0.17

0.44 ± 0.15

< 0.001

Medicines

 Aspirin, n (%)

177 (58.6)

154 (66.4)

23 (32.9)

0.002

92 (55.8)

85 (62.0)

0.147

 Statin, n (%)

145 (48.0)

122 (52.6)

23 (32.9)

0.004

81 (49.1)

64 (46.7)

0.681

 ACEI, n (%)

34 (11.3)

32 (13.8)

2 (2.9)

0.071

20 (12.1)

14 (10.2)

0.524

 ARB, n (%)

44 (14.6)

36 (15.5)

8 (11.4)

0.652

24 (14.5)

20 (14.6)

0.824

 Calcium Blocker, n (%)

60 (19.9)

48(20.7)

12 (17.1)

0.390

31 (18.8)

29 (21.2)

0.764

  1. Data are expressed as mean ± SD, median (25th–75th percentile) or n (%).Bold values indicate statistical significance. CAD coronary artery disease, CAP carotid atherosclerotic plaque, BMI body mass index, HTN hypertension, FPG fasting plasma glucose, HbA1C hemoglobin A1C, TC total cholesterol, LDL-C LDL cholesterol, HDL-C HDL cholesterol, TG triglyceride, Lp(a) lipoprotein(a), Hs-CRP high sensitivity C-reactive protein, LVEF left ventricular ejection fraction, FFAs free fatty acids, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us